NCT00475033View on ClinicalTrials.gov

Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants

PHASE3CompletedINTERVENTIONAL
Enrollment

603

Participants

Timeline

Start Date

June 30, 2007

Primary Completion Date

May 31, 2009

Study Completion Date

May 31, 2009

Conditions
Vaccines, Pneumococcal Conjugate Vaccine
Interventions
BIOLOGICAL

13-valent Pneumococcal Conjugate Vaccine

13-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.

BIOLOGICAL

7-valent pneumococcal conjugate vaccine

7-valent pneumococcal conjugate vaccine administered at 2-, 4-, 6-, and 12 months of age.

Trial Locations (11)

T3B 6A8

Calgary

T5N 4A3

Edmonton

V3C 4J2

Coquitlam

V3R 8P8

Surrey

V6H 3N1

Vancouver

R3A 1M3

Winnipeg

R3E 0W3

Winnipeg

B3K 6R8

Halifax

H3H 1P3

Montreal

H3T 1C5

Montreal

G1E 7G9

Québec

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00475033 - Study Evaluating 13-valent Pneumococcal Conjugate Vaccine in Healthy Infants | Biotech Hunter | Biotech Hunter